Skip to search formSkip to main contentSkip to account menu

Fuzeon

National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
Review
2016
Review
2016
The failures of several first‐generation and second‐generation small molecule drug‐based anti‐HIV therapies in various stages of… 
2014
2014
Fuzeon (Enfuvirtide, T20) is the first fusion inhibitor approved by the FDA of the USA for the treatment of HIV/AIDS in… 
2012
2012
Bone scintigraphy using Tc-99m methylene diphosphonate (MDP) was performed on a 16-year-old girl as a component of surveillance… 
Review
2010
Review
2010
Enfuvirtide (ENF, T-20, or Fuzeon [Hoffman-La Roche Inc, Nutley, NJ, and Trimeris, Inc, Durham, NC]) is an HIV-1 fusion inhibitor… 
2006
2006
The FDA changed the FUZEON prescribing information to help avoid this common and unpleasant side effect of the drug. 
2004
2004
In recent years, significant progress has been made towards the chemotherapy (and ?prophylaxis) of HIV infections. This progress… 
2004
2004
Zusammenfassung.Hintergrund:Die hochaktive antiretrovirale Therapie (HAART) hat die Mortalitätsrate von AIDS-Patienten in den… 
Review
2003
Review
2003
With the number of people living with HIV infection increasing and the problems of drug resistance and long‐term toxicity… 
2003
2003
The FDA approved enfuvirtide (Fuzeon) in spring 2003 to use with other anti-HIV drugs in children age six and older and in adults…